Back Antagonista de la aldosterona Spanish Antialdosteronici Italian 鉱質コルチコイド受容体拮抗薬 Japanese Antagonis reseptor mineralokortikoid Malay Blokery receptora aldosteronowego Polish Antagonista da aldosterona Portuguese Antimineralokortikoid Serbo-Croatian Zaviralci aldosteronskih receptorjev Slovenian Antimineralokortikoid Serbian Aldosteronantagonister Swedish
| Mineralocorticoid receptor antagonist | |
|---|---|
| Drug class | |
 Spironolactone, the most widely used antimineralocorticoid. | |
| Class identifiers | |
| Synonyms | Aldosterone antagonistic; Mineralocorticoid antagonist |
| Use | Diuretic; Chronic heart failure; Hypertension; Hyperaldosteronism; Conn's syndrome |
| Biological target | Mineralocorticoid receptor |
| Chemical class | Steroidal; Nonsteroidal |
| Legal status | |
| In Wikidata | |
A mineralocorticoid receptor antagonist (MRA or MCRA)[1] or aldosterone antagonist, is a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors. This group of drugs is often used as adjunctive therapy, in combination with other drugs, for the management of chronic heart failure. Spironolactone, the first member of the class, is also used in the management of hyperaldosteronism (including Conn's syndrome) and female hirsutism (due to additional antiandrogen actions). Most antimineralocorticoids, including spironolactone, are steroidal spirolactones. Finerenone is a nonsteroidal antimineralocorticoid.
- ^ The Krause/King-Lewis acronym, developed at Naval Medical Center San Diego Archived 2018-07-13 at the Wayback Machine, of MCRA was developed during February 2017 to distinguish between MRA for a specific MRI which are both widely recognized medical acronyms as compared to the use of MRA for mineralocorticoid receptor antagonist type medications which is only used as a medical acronym in the cardiology and nephrology word.
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search